KIT and small cell lung carcinoma: These discoveries demonstrate the crucial contribution of DNMT1 or KIT to cisplatin resistant phenotypes, supporting DNA hypomethylating agents and kinase inhibitors as therapeutic options in cisplatin-treated SCLC patients, which certainly merits further investigations.